Skip to main content
QURE logo

QURE · uniQure N.V.

Track QURE — free
$20.23 -0.07 (-0.34%)
Market Cap
$1.42B
Shares
70.14M
Volume · Nov 19 1.16M Avg daily vol (3M) 2.22M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$20.23 Open$20.57 Day$19.94–21.10 52W close$9.03–51.05 Avg vol 30d1.9M Short int8.5M · 12.1% of shares · 6.4d Short vol45% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Mar 1, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 11
Investor event
AMT-130 BLA accepted for priority review

Unicure's AMT-130 BLA was accepted for priority review; the company expects a confirmatory study of about 200 patients comparing treatment with standard of care at 36 months, while preparing for accelerated approval.

3 source passages
Very pleased to be here with Matt Capista from Unicure. Terrific. Great. So yeah, you just had some recent news where the BLA for AMT 130 was accepted with priority review. We expect about 200 patients to be in our sample size, and patients treated with AMT-130 will be compared at 36 months to these patients that are randomized in the standard of care to evaluate treatment benefits. Open the document at this passage
Nov 10
Investor event
AMT-130 shows durable functional capacity through 48 months

Unicure said high-dose AMT-130 patients maintained total functional capacity through 48 months, while the 200-patient confirmatory study is advancing with a 36-month endpoint.

4 source passages
And actually, if you look at the 48-month trends, the patients treated with high-dose AMT-130 haven't even lost on average 0.1 points per year. So, going back to the 200-patient study that. Should be underway shortly. Can you talk to the powering of the TFC, given that you're going to be a 36-month endpoint? The study is advancing very well. my privilege to welcome Matt Kapusta, the CEO of Unicure. Open the document at this passage
Nov 4
Earnings call
AMT-130 gains FDA priority review; cash runway reaches 2030

Unicure said AMT-130 entered FDA priority review with a target PDUFA date of May 1, 2027. Cash, cash equivalents, and investment securities totaled $768.4 million as of September 30, 2026 and are expected to fund operations into 2030.

3 source passages
AMT-130 in Huntington's disease, or HD. As Matt noted, the BLA is under priority review with the PDUFA date of May 1, 2027, and the MAA has been validated by the MHRA. Cash, cash equivalents, and investment securities totaled $768.4 million as of September 30, 2026, compared to $622.5 million as of December 31, 2025. Expect that cash, cash equivalents, and investment securities will be sufficient to fund operations into 2030. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA grants Priority Review for gene therapy

uniQure reported FDA acceptance of ifezuntirgene inilparvovec for Priority Review on November 2 2026, targeting May 1, 2027. The confirmatory study will enroll approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with a 36-month endpoint.

Revenue $5.2M ▲ 40.4% Net loss $61.22M Diluted EPS -$0.88
Read from the MD&A section
3 source passages
On November 2 2026, we announced the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, submitted under the Accelerated Approval pathway. The application has been granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) target action date of May 1, 2027. We and FDA have aligned on key elements of a confirmatory study design. The study is designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Function Capacity (“TFC”) as the primary endpoint at 36 months. our monetary assets and liabilities denominated in foreign currencies, principally the euro and the U.S. dollar. Open the document at this passage
Nov 4
Current report 8-K
AMT-130 receives FDA Priority Review for Huntington’s disease

uniQure N.V. received FDA Priority Review for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease, with a PDUFA target action date of May 1, 2027. Cash of $768.4 million as of September 30, 2026 is expected to fund operations into 2030.

Financial results
4 source passages
FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 The BLA was granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. As of September 30, 2026, the Company had cash, cash equivalents and investment securities of $768.4 million. The Company expects that these resources will be sufficient to fund projected operating expenses into 2030. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$20.17M
Trailing 12 months
Net income (TTM)
−$232.90M
Trailing 12 months
Revenue growth YoY
+40.4%
Year over year
Operating margin
-1,001.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$8.32M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.5%
Year over year · more shares
Price change (1Y)
-31.7%
Trailing year
Short interest
12.1%
Latest settlement · 6.4 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. AMT-130 received FDA Priority Review with a May 1, 2027 PDUFA date, the MHRA validated its U.K. application, the FDA-aligned confirmatory study is moving toward year-end screening, updated analyses showed disease-progression slowing, pipeline enrollment advanced, and $768.4 million in cash is expected to fund operations into 2030. Risks include the nonsignificant 48-month cUHDRS result, AMT-191's prior dosing pause, higher R&D and SG&A expenses, a $61.2 million net loss, and the possibility that FDA may find the Phase I/II data insufficient for approval.

Bullish
  • + Cash, cash equivalents and investment securities increased to $768.4 million and are expected to fund operations into 2030. new
Bearish
  • − Selling, general and administrative expenses increased $4.5 million year over year as the company built commercial capabilities. new
  • − The company reported a $61.2 million net loss for the third quarter of 2026. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross Death cross
Price vs 200-day avg −32%
below
Price vs 50-day avg −27%
below
RSI (14) 35
neutral
MACD trend Positive
52-week position 27%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −12%
trailing
6-month return −28%
trailing
YTD return −15%
this year
Relative strength −23%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $28 › 200d $30 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +43 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.13% of shares out · ▼ -2.5% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
249 holders — mid 3-yr range
Squeeze score 69
elevated · 0–100
Fundamentals
Fair
Revenue growth −48%
Y/Y
EPS growth +30%
Y/Y
Free cash flow $-178.4M
Balance sheet $8.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 132%
annualized · 1-yr
Max drawdown −68%
past year
ATR 8.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 1, 2024
Annual recurring cash burn · annual 40%
Previous outlook earlier release · from the 8-K filed Nov 7, 2023

Still-open targets the latest release did not restate under the same label.

Cost savings · over the next three years $180M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−32% Bearish
Price vs 50-day avg
−27% Bearish
RSI (14)
35 Neutral
MACD trend
Positive Bullish
52-week position
27% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) Death cross
50d $28 › 200d $30 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +43 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.13% of shares out · ▼ -2.5% MoM · 6.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
249 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $9 Now $20 · 27% Range high $51
vs 200-day avg -32% vs 50-day avg -27% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
aggregate gross proceeds $259M In June 2026 —
ordinary shares 5,686,813 In June 2026 —
patients across three dose levels 11 data cutoff date of March 15, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QURE
uniQure N.V.
this stock
$1.42B -15.5% -47.8% — 12.1%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
249
% held
85.6%
Net QoQ
-5.3M sh
Top holder
Avoro Capital Advisors LLC
Held Float
View
Held by Funds
Fund positions
25
View
Short & Settlement
Short Interest Falling
Shares short
8.5M
Days to cover
6.4d
Change
-219.1K sh
View
Short Volume
Short vol %
45%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
14.1K
Value
$300.4K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
43.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$13.1M
Net income (FY)
$-199.0M
EPS diluted
$-3.46
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
25

Unicure's AMT-130 BLA was accepted for priority review; the company expects a confirmatory study of about 200 patients comparing treatment with standard of care at 36 months, while preparing for accelerated approval.

View
Proposed Sales
Value
$193.0K
Shares
9.1K
Filed
Nov 6, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
uniQure Announces Third Quarter 2…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
QURE -17.9% -12.5% -28.3% -18.5% -15.5%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -12.4% -6.2% -22.7% -13.3% -20.4%
Key facts CIK 1590560 CUSIP N90064101 13F (30d) 268 filings 232 filers Visit website Investor relations